Lv1
90 积分 2020-11-18 加入
Neoadjuvant Pyrotinib plus Trastuzumab, Docetaxel, and Carboplatin in Early or Locally Advanced Human Epidermal Receptor 2-Positive Breast Cancer in China: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
7天前
已完结
Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial
7天前
已关闭
Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial
7天前
已完结
Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity
1个月前
已完结
The microbiota in radiotherapy-induced cancer immunosurveillance
2个月前
已完结
Neutrophils drive vascular occlusion, tumour necrosis and metastasis
3个月前
已完结
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
3个月前
已完结
BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes
4个月前
已完结
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
4个月前
已完结
Neuro-immune cross-talk in cancer
4个月前
已完结
皖公网安备34019202002308
